Odesivimab is a human monoclonal antibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection.
Odesivimab (REGN-3471) neutralizes pseudovirus particles in vitro. Odesivimab with Atoltivimab and Maftivimab has an IC50 value of 0.39 nM[1].
Odesivimab with Atoltivimab and Maftivimab (REGN-3471; 50 mg/kg) has protective effect in the rhesus macaque model of Ebola virus infection[1].
References:
[1]. Markham A. REGN-EB3: First Approval. Drugs. 2021 Jan;81(1):175-178.
















